Meribank Biotech Co., Ltd (TPEX:4724)

Meribank Biotech Revenue

Meribank Biotech had revenue of 187.13M TWD in the half year ending June 30, 2026, with 43.59% growth. This brings the company's total for the last twelve months to 408.48M, down -16.04% year-over-year. In the year 2025, Meribank Biotech had annual revenue of 471.76M with 28.75% growth. That makes Meribank Biotech the 36,290th largest company in the world by revenue and 1,896th in Taiwan.

• Revenue (ttm): 408.48M
• Revenue Growth: -16.04%
• P/S Ratio: 2.05
• Revenue / Employee: 2.88M
• Employees: 142
• Market Cap: 837.87M

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Stem Cell Department 246.16M 52.2%
• Management Consulting Department 159.76M 33.9%
• Other 65.85M 14.0%

Fiscal year ended Dec 31, 2025 See the full Meribank Biotech breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	471.76M	105.33M	28.75%
Dec 31, 2024	366.43M	132.09M	56.37%
Dec 31, 2023	234.34M	54.22M	30.10%
Dec 31, 2022	180.12M	17.04M	10.45%
Dec 31, 2021	163.08M	-31.32M	-16.11%

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Oct 26, 2026

Data Sources Report a data error